Latest & greatest articles for amlodipine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amlodipine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amlodipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amlodipine

1. Amlodipine

Amlodipine Top results for amlodipine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for amlodipine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Efficacy of isoproterenol for treating amlodipine overdose resulting in bradycardia

Efficacy of isoproterenol for treating amlodipine overdose resulting in bradycardia 29123890 2018 11 13 2052-8817 4 3 2017 07 Acute medicine & surgery Acute Med Surg Efficacy of isoproterenol for treating amlodipine overdose resulting in bradycardia. 353-357 10.1002/ams2.284 Amlodipine predominantly affects vascular smooth muscle cells. Amlodipine overdose usually presents with vasodilatory shock, accompanied by reflex tachycardia rather than bradycardia.An 81-year-old woman presented (...) with impaired consciousness 8 h after ingesting 50 5-mg amlodipine tablets with suicidal intent. On admission, her blood pressure was 50/40 mmHg and her heart rate was 45 b.p.m. Serum amlodipine level was extremely high (474.4 ng/mL), causing refractory bradycardia. She remained hypotensive despite fluid resuscitation, and therefore was administered dopamine and norepinephrine. She was also administered glucagon and calcium gluconate, and underwent high-dose insulin euglycemic therapy. Although her blood

Acute medicine & surgery2017 Full Text: Link to full Text with Trip Pro

3. Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study

Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study 27747834 2018 11 13 2199-1154 3 3 2016 Sep Drugs - real world outcomes Drugs Real World Outcomes Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study. 307-315 EXCITE (clinical experience of amlodipine and valsartan in hypertension) evaluated the (...) real-world effectiveness and safety of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from the Middle East and Asia. The objective of this study was to report the results of EXCITE study from Egypt, where all patients were prescribed Aml/Val. This was a 26-week, observational, multicenter, prospective, non-interventional, open-label study. Effectiveness was assessed as change in the mean

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

4. perindopril arginine / amlodipine (Viacoram)

perindopril arginine / amlodipine (Viacoram) perindopril arginine / amlodipine | CADTH.ca Find the information you need perindopril arginine / amlodipine perindopril arginine / amlodipine Last Updated: Result type: Reports Project Number: SR0490-000 Product Line: Generic Name: perindopril arginine / amlodipine Brand Name: Viacoram Manufacturer: Servier Canada Inc. Indications: Hypertension, essential Submission Type: New Project Status: Active Date Recommendation Issued: October 26, 2016

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

5. Amlodipine / Valsartan Mylan - hypertension

Amlodipine / Valsartan Mylan - hypertension 28 January 2016 EMA/CHMP/182030/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Amlodipine/Valsartan Mylan International non-proprietary name: amlodipine / valsartan Procedure No. EMEA/H/C/004037/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone (...) /National Formulary UV Ultraviolet light Assessment report EMA/CHMP/182030/2016 Page 4/31 1. Background information on the procedure 1.1. Submission of the dossier The applicant MYLAN S.A.S. submitted on 20 January 2015 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Amlodipine/Valsartan Mylan, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004 – ‘Generic of a Centrally authorised product’. The eligibility to the centralised

European Medicines Agency - EPARs2016

6. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud`s phenomenon: a double-blind, randomized, cross-over study

Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud`s phenomenon: a double-blind, randomized, cross-over study 24352340 2014 03 21 2014 05 07 2014 03 21 1462-0332 53 4 2014 Apr Rheumatology (Oxford, England) Rheumatology (Oxford) Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study. 658-64 10.1093/rheumatology/ket417 RP is a reversible vasoconstriction of digital (...) arteries that causes pain and skin discoloration. This study compared the efficacy of the new phosphodiesterase type 5 inhibitor udenafil with that of the calcium channel blocker amlodipine in the treatment of secondary RP. A total of 29 patients with secondary RP associated with connective tissue diseases were enrolled in this double-blind, randomized, cross-over study. The patients were randomized to receive udenafil 100 mg/day or amlodipine 10 mg/day for 4 weeks. After a washout period they were

EvidenceUpdates2014

7. Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (Sevikar HCT) - In adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.

Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (Sevikar HCT) - In adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.

Scottish Medicines Consortium2012

8. [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Aliskiren / Amlodipin – Nutzenbewertung gemäß § 35a SGB V [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Aliskiren / Amlodipin – Nutzenbewertung gemäß § 35a SGB V [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social (...) Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Aliskiren / Amlodipin – Nutzenbewertung gemäß § 35a SGB V. [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und

Health Technology Assessment (HTA) Database.2012

9. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial

Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial 22897460 2012 08 17 2012 12 14 2013 11 21 1742-1241 66 9 2012 Sep International journal of clinical practice Int. J. Clin. Pract. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial. 834-42 10.1111/j.1742-1241.2012.02967.x To assess the extent (...) of reduction in blood pressure (BP) of aliskiren/amlodipine combination therapy compared with amlodipine monotherapy in moderate-to-severe hypertensive patients. This was an 8-week multicentre, randomised, double-blind study. After a 1-to 4-week washout period, eligible patients [mean sitting systolic blood pressure (msSBP) ≥ 160 to < 200 mmHg] were randomised to receive a once-daily dose of aliskiren/amlodipine 150/5mg (n = 244) or amlodipine 5 mg (n = 241) for 1 week, followed by up-titration

EvidenceUpdates2012

10. A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension

A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension 22805271 2012 07 18 2012 07 18 1742-1241 66 8 2012 Aug International journal of clinical practice Int. J. Clin. Pract. A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension. 792-799 10.1111/j.1742-1241.2012.02943.x Background: Chinese Hypertension Intervention Efficacy (CHIEF) study (...) is a large-scale randomised clinical trial across China, which compares the efficacy of two combination regimens in reducing cardiovascular events associated with hypertension. Methods: We reported the 48-week efficacy and tolerability of the two antihypertensive regimens in participants from Shandong Province, China. Eligible patients aged 50-79 years were randomised to receive amlodipine plus amiloride/hydrochlorothiazide (Group A) or amlodipine plus telmisartan (Group B). The doses of both regimens

EvidenceUpdates2012

11. Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials

Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials Richy FF, Laurent S CRD summary The review concluded that the efficacy/safety profile of manidipine was superior to amlodipine in patients with hypertension. Potential for (...) biases within the review and uncertain quality of the evidence base limits the reliability of the pooled results. Authors' objectives To compare the efficacy and safety of manidipine versus amlodipine in patients with hypertension. Searching PREMEDLINE, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 1995 to July 2009. A manual search of the literature and congress abstracts was undertaken. Leading authors were contacted for unpublished data

DARE.2012

13. Simvastatin: dose limitations with concomitant amlodipine or diltiazem

Simvastatin: dose limitations with concomitant amlodipine or diltiazem Simvastatin: dose limitations with concomitant amlodipine or diltiazem Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Simvastatin: dose limitations with concomitant amlodipine or diltiazem From: Published: 30 October 2012 Therapeutic area: and The maximum recommended dose for simvastatin in conjunction with amlodipine and diltiazem is now 20 mg/day. Article date: October 2012 Pharmacokinetic (...) data Simvastatin is metabolised through the CYP3A4 pathway. Concomitant use of CYP3A4 inhibitors has the potential to increase exposure to simvastatin . Both amlodipine and diltiazem are substrates and inhibitors of CYP3A4 and therefore increase the plasma concentration (AUC0-24h) and maximum plasma concentration (Cmax) of simvastatin when they are co-administered. Studies have found that after 10 days of amlodipine (10 mg), the AUC0-24h of simvastatin and simvastatic acid following a single dose

MHRA Drug Safety Update2012

14. Aliskiren / amlodipine - Benefit assessment according to § 35a Social Code Book V

Aliskiren / amlodipine - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (“Aliskiren/Amlodipin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status10.02.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports - Commission No. A11-29 Aliskiren / amlodipine – Benefit (...) assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A11-29 Version 1.0 Aliskiren / amlodipine - Benefit assessment acc. to § 35a Social Code Book V 10.02.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Aliskiren /amlodipine - Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 14.11.2011

Institute for Quality and Efficiency in Healthcare (IQWiG)2012

15. Randomised controlled trial: Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy

Randomised controlled trial: Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy Article Text Therapeutics

Evidence-Based Medicine (Requires free registration)2011

16. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. 21236483 2011 01 24 2011 03 17 2015 06 16 1474-547X 377 9762 2011 Jan 22 Lancet (London, England) Lancet Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. 312-20 10.1016/S0140-6736(10)62003-X Short-term (...) studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy. We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries

Lancet2011

17. Onduarp - telmisartan / amlodipine

Onduarp - telmisartan / amlodipine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. 22 September 2011 EMA/891763/2011 Committee for Medicinal Products for Human Use (CHMP) Assessment report Onduarp International non-proprietary name (...) : telmisartan / amlodipine Procedure No. EMEA/H/C/002118 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Medicinal product no longer authorisedTable of contents 1. Background information on the procedure 4 1.1 Submission of the dossier 4 Information on Paediatric requirements 4 Information relating to orphan market exclusivity 4 Scientific Advice 4 Licensing status 4 1.2 Steps taken for the assessment of the product 5 2. Scientific discussion 6 2.1

European Medicines Agency - EPARs2011

18. Rasitrio - aliskiren / amlodipine / hydrochlorothiazide

Rasitrio - aliskiren / amlodipine / hydrochlorothiazide 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report for Rasitrio International non-proprietary name: aliskiren / amlodipine / hydrochlorothiazide Procedure No. EMEA/H/C/002017 Assessment Report as adopted by the CHMP with all information of a commercially (...) radioisotope ABPM ambulatory blood pressure monitoring ACE Angiotensin converting enzyme ACE angiotensin-converting enzyme ADME Absorption, distribution, metabolism and excretion ADR adverse drug reaction AE adverse event Al Aluminium Ali aliskiren ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Aml amlodipine Ang angiotensin AR1 Autoregressive order 1 ARB Angiotensin receptor blocker ARB angiotensin receptor blocker ATR Attenuated Total Reflection AUC area under

European Medicines Agency - EPARs2011

19. Rasilamlo - aliskiren / amlodipine

Rasilamlo - aliskiren / amlodipine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report for Rasilamlo International Nonproprietary Name: aliskiren / amlodipine Procedure No. EMEA/H/C/002073 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Medicinal product (...) requested the relevant documentation as follow-up measure. The results from these additional studies were not considered required by the Committee before the adoption of the positive CHMP opinion and it is confirmed that these applications comply with Article 6 of Regulation 726/2004 having regard to the requirements of Article 8(3) (ca) of Directive 2001/83. 2.3.6. Discussion on non-clinical aspects No specific studies with the aliskiren/amlodipine fixed combination have been conducted concerning

European Medicines Agency - EPARs2011

20. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study

Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study 20716145 2010 08 18 2011 11 23 2015 11 19 1742-1241 64 10 2010 Sep International journal of clinical practice Int. J. Clin. Pract. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. 1367-74 10.1111/j.1742-1241.2010.02480.x A majority of hypertensive patients require > or = 2 agents to achieve target (...) blood pressure (BP). This 52-week, multicentre, open-label, randomised extension trial to a previously reported double-blind, placebo-controlled study evaluated the safety and efficacy of amlodipine/valsartan (Aml/Val) combination. Patients who successfully completed the core study without serious drug-related adverse events (AEs) and mean sitting systolic BP (MSSBP)/mean sitting diastolic BP (MSDBP) < or = 150/95 mmHg were eligible to enter the extension and be treated with Aml/Val 2.5/80 or 5/80

EvidenceUpdates2010